Published in State and Local Health Law Weekly, September 18th, 2008
Under the agreement, the parties will collaborate in the clinical development efforts for Rebamipide in the United States, with Acucela spearheading the regulatory strategy to gain approval for the product in the United States. Upon regulatory approval of Rebamipide, the parties may negotiate the terms under which Acucela may co-promote Rebamipide with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of State and Local Health Law Weekly